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Introduction
Increased mitochondrial production of reactive oxygen species (ROS) is usually linked to deleterious consequences involved in several pathophysiological settings including ischemia/reperfusion (I/R) injury (Halestrap et al., 2007) . However, the consequences of increased ROS during hypoxic periodes are complex and apparently ambivalent Halestrap et al., 2007) : while ROS are unambiguously involved in damaging cardiac tissue upon reperfusion, transient ROS generation seems to be essential for signalling during ischemic and pharmacological preconditioning, cardioprotective mechanisms that attenuate I/R injury. There are indications that ROS produced at the Q o site of mitochondrial complex III are involved in ischemic and pharmocological preconditioning (Vanden Hoek et al., 1998; Oldenburg et al., 2003) , but the underlying molecular mechanism is as unclear as the nature of the generators of deleterious ROS during reperfusion. Recently, we presented a straightforward rationale to mechanistically explain the ambivalent effects of the cardioprotective K ATP channel opener diazoxide on mitochondrial ROS generation (Dröse et al., 2009 ). On one hand, diazoxide that also inhibits mitochondrial complex II (Schäfer et al., 1971; Hanley et al., 2002; Dröse et al., 2006) directly attenuates ROS-generation by succinate fueled rat heart mitochondria due to reverse electron transfer (RET) from complex II into complex I. On the other hand, diazoxide stimulates superoxide production at the Q o site of complex III under conditions of 'oxidant-induced reduction', i.e. in presence of the Q i site inhibitor antimycin A (Dröse et al., 2009 ). This stimulation that has been confirmed in an independent study (Liu et al., 2010) can be explained by increased oxidation of the Q-pool following complex II inhibition. We have shown that ROS generation at Q o site of complex III is maximal if the Q-pool is partially reduced implying that superoxide is generated by ‛ reverse electron transfer' from reduced heme b L to molecular oxygen whith ubiquinone serving as a redox-mediator (Dröse and Brandt, 2008) . These findings were supported by investigations of the Osyczka group (Borek et al., 2008; Sarewicz et al., 2010) . Our proposed MOL #70342 mechanism contradicts the view that a semiquinone intermediate formed during normal turnover at the Q o site of complex III is the electron donor for superoxide (Muller et al., 2002; Cape et al., 2009 ).
Another controversly discussed issue concerns the question whether diazoxide exerts its cardioprotective effects solely via complex II inhibition and ROS generation (Hanley et al., 2002; Dröse et al., 2006; Dröse et al., 2009) or if a putative mitochondrial K ATP channel is involved as an independent effector (Liu et al., 2010) , an upstream regulator (Oldenburg et al., 2003) or downstream target (Facundo et al., 2007; Pasdois et al., 2008) of IPC and PPC induced ROS. Recently, it was proposed that complex II may be a component or regulator of the mitoK ATP channel (Ardehali et al., 2004; Wojtovich and Brookes, 2009) . It was shown that the highly potent and specific inhibitor atpenin A5 (Miyadera et al., 2003 ) that binds to the ubiquinone binding site of complex II (Horsefield et al., 2006) had the same cardioprotective effects in cardiomyocytes and Langendorff-perfused rat hearts as ischemic preconditioning, diazoxide and malonate (Wojtovich and Brookes, 2009 ). The effect of atpenin A5 was independent of complex II inhibition and the authors suggested that opening of the putative mito K ATP channel is the underlying mechanism. An alternative explanation was given by Jaggar and coworkers (Adebiyi et al., 2008) 
Materials and Methods
Materials. DQA (2-n-decyl-quinazolin-4-yl-amine, SAN 549) was obtained from AgrEvo (Frankfurt, Germany), amplex red (N-acetyl-3,7-dihydrophenoxazine) was purchased from Invitrogen/ Molecular Probes (Eugene, OR) and atpenin A5 was from Alexis Biochemicals (Lausen, Switzerland). Fatty acid free bovine serum albumin (BSA) was from SERVA (Heidelberg). Superoxide dismutase (SOD, from bovine liver), horseradish peroxidase (HRP), 2-thenoyltrifluoroacetone (TTFA), diazoxide (7-chloro-3-methyl-4H-1,2,4-benzothiadiazine 1,1-dioxide), stigmatellin and all other chemicals were from Sigma-Aldrich (Taufkirchen).
Diazoxide, atpenin A5, antimycin A, DQA, stigmatellin, TTFA, FCCP (carbonyl-cyanide-ptrifluoro-methoxy-phenylhydrazone), oligomycin and amplex red were dissolved in DMSO.
Since diluted atpenin A5 solutions had a limited stability, they were freshly prepared from a 1 mM stock before starting the experiments.
Preparation of submitochondrial particles. Submitochondrial particles from bovine heart mitochondria were prepared as previously described (Dröse et al., 2006) . The preparations had a protein concentration of 33.6 mg/ml (27.4 µM haem b and 71.6 µM haem aa 3 ) and 18.2 mg/ml (32.3 µM haem b and 35.3 µM haem aa 3 ), respectively.
Isolation of intact rat heart mitochondria. Rat heart mitochondria (RHM) were isolated at 4 ˚C as previously reported (Dröse et al., 2006 and 2 µg/ml oligomycin. As we have previously described and discussed in more detail (Dröse et al., 2009) , the ROS generation of intact and highly coupled rat heart mitochondria strongly depends on the quality of the preparation and the time elapsed between completion of the preparation protocol and the actual start of the ROS measurement. with one type of inhibitor were done at the same time, usually in combination with a second inhibitor (pairs were atpenin A5/TTFA and diazoxide/malonate). The maximal time between two sets of 20 min measurements was 15 min; thus all data were obtained within one hour after completion of the respective RHM preparation. However, the immediate application of the RHM inevitably resulted in some variation in the protein amount per assay, which might be in part responsible for the relatively high standard deviations under some conditions (see below), especially for the high affinity inhibitor atpenin A5.
Measurement of mitochondrial respiration. The rate of mitochondrial respiration was monitored at 25 °C using an Oxygraph-2k system (Oroboros, Innsbruck, Austria), equipped with two chambers and DatLab software version 4.2. Rat heart mitochondria (0.12 -0.33 mg protein) were added to 2 ml of a buffer containing 200 mM sucrose, 10 mM potassium or sodium phosphate (pH 7.0), 10 mM Tris/HCl, 10 mM MgSO 4 , and 2 mM EDTA. The mitochondria were fueled by 4.8/5.6 mM malate/glutamate. The respiratory control factor (RCF) was determined as ratio between state 3 and state 4 respiration after addition of 2 mM ADP. For the determination of succinate-oxidase inhibition, 100 µM ATP and 5 mM succinate (in the absence of complex I inhibitors) were added and the measurements were performed at the same time as the related amplex red/HRP assays.
Succinate oxidase activity. Submitochondrial particles (240 µg of protein) were added to a 2 ml reaction mixture containing 75 mM sodium-phosphate (pH 7.4), 1 mM MgCl 2 , 1 mM EDTA, and 5 mM sodium succinate. Note that the SMP concentration was identical to that in the amplex red/HRP assay, since especially for the high affinity complex II inhibitor atpenin A5 some influence of the protein concentration on the resulting I 50 value was observed (not shown). Oxygen consumption was measured at 25 °C using the Oxygraph-2k system. This article has not been copyedited and formatted. The final version may differ from this version. (Schäfer et al., 1971) , but its exact binding site is not known. In a first set of experiments we analyzed, if also the inhibitors atpenin A5 and TTFA that bind to the Q-site of complex II (Miyadera et al., 2003; Horsefield et al., 2006) affect ROS production of bovine SMP (Fig. 2) . SMPs have the advantage that involvement of a putative mitochondrial K ATP channel can be excluded, that electrons can be fed directly into the different respiratory chain complexes, and that ROS production can be detected quantitatively with the amplex red/HRP assay without any interference of the mitochondrial ROS defense system. While TTFA did increase the background fluorescence of the amplex red/HRP assay, neither the kinetic rates nor the resolution of the assay were affected by the addition of TTFA per se (results not shown). Both inhibitors did not markedly affect the ROS production when electrons were supplied via complex I (by NADH) or complex III (by n-decyl-ubiquinol; results not shown) as had been observed previously with oxaloacetate, malonate or diazoxide (Dröse and Brandt, 2008; Dröse et al., 2009 considerably stimulated ROS generation at the Q o site of complex III (Fig. 2 B) . This increase was completely sensitive to the Q o site inhibitor stigmatellin (not shown) and correlated well with the degree of succinate oxidase inhibition. A marked increase occurred when succinate oxidase was inhibited more than 75 %. The highest rates were detected when 80-90 % of the activity was inhibited at 100 µM TTFA or 20 nM atpenin A5. At near complete inhibition the rates decreased again (i.e. with 50 nM atpenin A5). This is consistent with the model that the redox state of the Q-pool controls superoxide production of the Q o site of complex III that is maximal with a partially oxidized Q-pool as induced by complex II inhibition under these conditions (Dröse and Brandt, 2008) . Furthermore, these results are in accordance with results obtained with oxaloacetate, malonate and diazoxide (Dröse and Brandt, 2008; Dröse et al., 2009 ) indicating that just the degree of complex II inhibition and the resulting oxidation of the Q-pool controls ROS production by complex III, but not the binding site or the mechanism of inhibition.
Effect of different complex II inhibitors on ROS production by coupled rat heart mitochondria. Only highly coupled RHM preparations were used in our investigation (respiratory control factors with malate/glutamate as substrates were at least 10). All measurements were performed in a buffer containing 100 µM ATP but omitting the complex V inhibitor oligomycin that is usually included in studies dealing with the putative mito K ATP channel, since this represents more physiological conditions (Riess et al., 2008) and also bypasses complications due to the induction of a high rate of RET-induced ROS production when succinate is the predominant substrate (Dröse et al., 2009) . As previously observed with diazoxide and malonate (Dröse et al., 2006; Dröse et al., 2009 ), TTFA and atpenin A5 had no effect on mitochondrial ROS production when the respiratory chain was fueled via complex I by malate and glutamate (results not shown). In a potassium containing buffer, all four tested complex II inhibitors had ambivalent effects on mitochondrial H 2 O 2 production when This article has not been copyedited and formatted. The final version may differ from this version. succinate was the substrate (Fig. 3A and 4 ). Fig. 3 shows a representative set of data obtained with a single RHM preparation to reveal differences in the rates of ROS production. To illustrate the effect of batch dependent variations Fig. 4 summarizes the changes relative to the respective basal rate with three different biological samples. If succinate was applied as the sole electron donor for the respiratory chain, a H 2 O 2 production rate of around 100 pmol mg -1 min -1 (variation 44 -234 pmol mg -1 min -1 , n=6) was detected. This can be attributed completely to ROS generation by complex I due to reverse electron transfer from complex II, since it was sensitive to the complex I inhibitor DQA and to uncoupling by 50 nM FCCP (Suppl. Fig. 1 ). In contrast, the addition of the complex V inhibitor oligimycin increased the rate 5-7 fold (Suppl. Fig. 1 ). This indicated that the high membrane potential required as the driving force for RET-induced ROS production (Votyakova and Reynolds, 2001 ) was already reduced by the addition of ATP that was probably partly hydrolyzed to ADP. All complex II inhibitors attenuated ROS production ( Fig. 3A and 4) . A comparison with the inhibition of succinate oxidase activity revealed that an inhibition by only 25 % was sufficient to almost completely impede complex I related ROS production under these conditions. If the respiratory chain was inhibited by a Q i site inhibitor of complex III (antimycin A), ROS production switched from complex I (due to the reduction of ΔΨ) to the Q o site of complex III (Dröse et al., 2009) . A reduction in complex II activity now caused an increase in mitochondrial ROS production at the Q o site of complex III ( Fig. 3 and 4) . This can be explained by an increased oxidation of the Q-pool due to complex II inhibition that favours superoxide production at the Q o site of complex III from reduced heme b L (Dröse and Brandt, 2008) . The data for atpenin A5, TTFA and diazoxide indicated that there was a clear correlation of complex II inhibition and stimulation of the antimycin A induced ROS production under these conditions. Already at moderate inhibition of complex II, a slight increase of the rate could be observed. The highest rates were detected when succinate oxidase was inhibited by more than 50 % by TTFA and Atpenin A5 and a stimulation of the This article has not been copyedited and formatted. The final version may differ from this version. antimycin A induced ROS-production up to ~ 1 nmol mg -1 min -1 (range 0.6 -1.4 nmol mg -1 min -1 , n=6) was observed. In contrast, diazoxide exerted only ~ 20 % inhibition at the highest applied concentration of 100 µM (Fig. 4) resulting in a moderate increase of the ROS production. A somewhat different relation was observed for malonate: while the maximal concentration of 1.5 mM inhibited succinate oxidase by 75 %, the antimycin A induced ROS production was only stimulated to the level of diazoxide. This difference may be due to the requirement of a membrane potential or ΔpH for the carrier-mediated uptake of the dicarboxylate acid malonate into the mitochondrial matrix that was present in the respiratory measurements with succinate ( Fig. 3B ) but impeded in the ROS measurements by the addition of antimycin A (Fig. 3A) . In SMP, the same malonate concentrations stimulated the antimycin A induced ROS production to a much higher degree and much more effectively than , n=6). Especially under these conditions it was obvious that further inhibition of complex II and hence further oxidation of the Q-pool resulted in a reduction of the H 2 O 2 production, giving the complex II inhibitor profiles a bell-shaped appearance. The emerging picture from these measurements is that all tested complex II inhibitors had ambivalent effects on ROS production of intact RHM respiring on succinate and that their specific characteristics were directly related to their potency of complex II inhibition. ). Furthermore, also the atpenin A5-dependent attenuation of the ROS production at complex I due to RET should only occur with potassium-containing buffer if the putative mitoK ATP channel was involved. However, overall the effects of atpenin A5 and TTFA on ROS generation and inhibition of state 4 respiration were quite similar in potassium-and sodium-containing buffers ( Fig. 5 and 6 ). There was even a general trend that the H 2 O 2 production rates in sodium-containing buffer were slightly higher than in potassiumcontaining buffer. Also respiratory rates and coupling rates of the RHM were largely unaffected (results not shown). In most preparations a shift towards somewhat lower complex II inhibitor concentrations for 'maximal ROS production' in the sodium-containing buffer was observed. However, this was not always obvious, since also other factors like the actual protein concentration in the assay affected the inhibitor-ROS production ratio, especially in case of the tight binding inhibitor atpenin A5. These data clearly indicated that potassium ions did not affect the ability of atpenin A5 and TTFA to modulate mitochondrial ROS production in an ambivalent way when succinate was the predominant substrate. Hence, our data indicate that the inhibitors induced substrate dependent stimulation or attenuation of the superoxide production by direct inhibition of complex II.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Our results demonstrate that all complex II inhbitors despite their different binding sites ( Fig.   1 ) and a wide range of affinities affected ROS production by the respiratory chain in the same way. All compounds exhibited comparable ambivalent effects when succinate was the predominant substrate: they attenuated ROS production at the level of complex I by reverse electron transfer while they stimulated ROS generation at the Q o site of complex III under conditions of 'oxidant-induced reduction'. In this respect, complex II activity modulates these two respiratory chain complexes (Dröse et al., 2009 ) that are generally regarded as the main ROS producers within mitochondria (Kowaltowski et al., 2009; Brand, 2010) . A common principle exerting these effects seems evident, since we observed a strict correlation between the degree of inhibition and the modulating effects on ROS production for all compounds.
Three of the investigated complex II inhibitors have been shown to be cardioprotective in concentrations (Burwell et al., 2009 ) that are in good agreement with those affecting ROS production of RHM. Since ROS play a central role in preconditioning as well as in cardiac damage (Halestrap and Pasdois, 2009 ), a link between mitochondrial ROS modulation and cardioprotection seems plausible. Furthermore, our data question the recently proposed role of complex II in the composition or regulation of the putative mitochondrial K ATP channel (Ardehali et al., 2004; Wojtovich and Brookes, 2009) , since for none of the inhibitors tested including atpenin A5 we observed an effect of K + ions on the ambivalent modulation of ROS production.
If succinate is the main substrate of mitochondria, ROS are predominantly produced at complex I due to reverse electron transfer against the gradient of redox potentials from complex II via ubiquinone to complex I which requires a high membrane potential as the driving force (Votyakova and Reynolds, 2001) . According to our model (Dröse et al., 2009), this is the predominant mode of ROS production upon reperfusion after succinate This article has not been copyedited and formatted. The final version may differ from this version. (Starkov, 2008) . As can be seen from our results, already a moderate inhibition of complex II by ~ 25 % can minimize ROS production due to RET, probably by reducing ΔΨ and the supply of electrons. This is in agreement with the observation that already a small drop of ΔΨ by only 5 % can reduce the ROS generation by 95 % (Votyakova and Reynolds, 2001 ).
Compared to the other complex II inhibitors, diazoxide seems to be more potent, minimizing complex I ROS generation even at a lower degree of complex II inhibition. While this could in principle be explained by the (additional) opening of a mito K ATP channel, which would also reduce ΔΨ, our previous studies have shown that the effects of diazoxide are not potassium dependent (Dröse et al., 2009) . It seems more likely that the weak uncoupling properties of diazoxide have to be considered here (Holmuhamedov et al., 2004; Dröse et al., 2006; Kopustinskiene et al., 2010) , since also uncoupling attenuates ROS generation by RET.
Since complex I releases superoxide completely into the mitochondrial matrix (St Pierre et al.,
2002) reducing its ROS production by complex II inhibitors or uncouplers would largely attenuate production of deleterious ROS. On the matrix site, ROS can not only damage mitochondrial DNA, they are also a main determinant for the opening of the mitochondrial permeability transition pore which seems to be involved in reperfusion injury (overview in (Halestrap and Pasdois, 2009) ). The recently published X-ray structural analysis of mitochondrial complex I (Hunte et al., 2010) indicates that the ubiquinone reduction site is located ~25
Ả above the membrane plane in the peripheral arm. Thus, even if mitochondrial complex I generates superoxide not exclusively at the tightly bound FMN (Galkin and Brandt, 2005; Kussmaul and Hirst, 2006) , but also at the ubiquinone binding site (Lambert and Brand, 2004; Brand, 2010) , superoxide would have to be released into the matrix also from this site.
This article has not been copyedited and formatted. The final version may differ from this version. (Dröse and Brandt, 2008; Borek et al., 2008; Sarewicz et al., 2010) . These results are in line with our proposal that complex II might regulate the generation of signalling ROS at complex III during the preconditioning phase (Dröse et al., 2009) . Experimental data indicate that ROS produced at the Q o site of complex III are involved in ischemic and pharmacological preconditioning (Vanden Hoek et al., 1998; Oldenburg et al., 2003) . This is also in good agreement with the fact that ROS produced at the Q o site are predominantly released into the intermembrane space (St Pierre et al., 2002; Muller et al., 2004) , where they could turn on protective cellular pathways without damaging the mitochondrial DNA or inducing mPTP opening (Dröse et al., 2009 ).
Several published data support the notion that the ambivalent effects of complex II inhibitors observed in our in vitro systems also occur under physiological conditions, i.e. in cardiomyocyte cultures or in Langendorff perfused rat hearts. It was shown in two initial studies that generation of diazoxide-as well as the hypoxia-induced ROS in the preconditioning phase was attenuated by the Q o site inhibitor myxothiazol (Vanden Hoek et al., 1998; Oldenburg et al., 2003) . Furthermore, Dos Santos and colleagues (Pasdois et al., 2008 ) observed a transient increase of ROS generation in perfused hearts during preconditioning with diazoxide, while it also decreased ROS produced during reperfusion. It has also been shown that diazoxide and malonate can attenuate ROS generation occuring after and during a longer ischemic period and upon reperfusion in isolated rat heart mitochondria (Ozcan et al., 2002) . cardioprotective action, or if a mitochondrial K ATP channel is involved or is even a determining factor. This is controversially discussed and often the non-specific action of the applied drugs like diazoxide is an issue (Hanley et al., 2002; Halestrap et al., 2007) . Recently it was proposed that complex II is involved in the composition or regulation of the mito K ATP channel (Ardehali et al., 2004; Wojtovich and Brookes, 2009 ). Marban and colleagues isolated a multi-enzyme complex from rat liver mitochondria that showed pharmacological characteristics of the proposed mitoK ATP channel, contained complex II and transported potassium when reconstituted into proteoliposomes (Ardehali et al., 2004) . Unfortunately, not all proteins of the multi-enzyme complex were identified and the identity of the potassium transporting protein is still obscure. An important study showed that the highly potent and specific complex II inhibitor atpenin A5 had the same cardioprotective effects as ischemic preconditioning, diazoxide and malonate in cardiomyocytes and in Langendorff-perfused rat hearts (Wojtovich and Brookes, 2009 ). The authors suggested a functional association of the mitoK ATP channel and complex II which seems to be supported by the broad pharmacological overlap between the two proteins (Burwell et al., 2009) . While the studies in cardiomyocytes and isolated hearts clearly showing the cardioprotective effect of atpenin A 5 represent more physiolocical conditions than the in vitro study presented in this paper, a significant portion of the results in this work were also obtained under in vitro conditions, e.g. an osmotic swelling assay with isolated mitochondria was used to monitor the K ATP channel activity and the inhibition of complex II activity (Wojtovich and Brookes, 2009) . Moreover, complex II activity but not osmotic swelling was assayed in the presence of rather high concentrations of ubiquinone-2 which may have affected the efficiency of a competitive inhibitor like atpenin A5 (Horsefield et al., 2006) . Our data suggest an alternative explanation for the cardioprotective effect of the tested complex II inhibitors by direct modulation of complex II activity resulting in ambivalent effects on mitochondrial ROS generation. In line with our proposed model for the production This article has not been copyedited and formatted. The final version may differ from this version. Our model can even explain why an attenuation of the diazoxide effect was observed after application of 1 µM atpenin A5 (Adebiyi et al., 2008) : at this high atpenin concentration complex II is expected to be inhibited completely and the Q-pool will be highly oxidized. As a consequence only little ROS could be produced at the Q o site of complex III. and D (CybS) (Sun et al., 2005; Miyadera et al., 2003) , the succinate analog malonate binds to the substrate (succinate) binding site located in subunit A (flavoprotein). Kinetic data indicate that the K ATP channel opener diazoxide inhibits complex II with respect to succinate in a non-competitive manner (Schäfer et al., 1971) , but the exact binding site is not known. complex II inhibitors (atpenin A5, ; TTFA, ; malonate, ; diazoxide, ) on the succinate-oxidase activity of this RHM preparation was monitored in the identical buffer by an Oxygraph-2k. The respiratory rate (pO 2 ) was 5.8 ± 0.4 nmol mg -1 min -1 (n = 4). ( ), respiratory rate (pO 2 ) was 6.1 ± 0.4 nmol mg -1 min -1 (n = 4 for each inhibitor, overall n = 12). detected by the amplex red/HRP assay. General conditions as described in legend of Fig. 3. (B) The effects of the complex II inhibitors on the succinate-oxidase activity of the respective RHM preparation was monitored by an Oxygraph-2k: K + buffer ( ), Na + buffer ( ). The respiratory rates were 3.5 ± 1.4 nmol mg -1 min -1 for the K + and 3.6 ± 1.4 nmol mg -1 min -1 for the Na + buffer (n = 2 for each buffer). shown; each of the duplicates per assay was treated independently (hence n=6). Inhibition of succinate-oxidase: ( ), respiratory rates (pO 2 ) were 5.9 ± 2.1 nmol mg -1 min -1 for the K + and 5.7 ± 1.8 nmol mg -1 min -1 for the Na + buffer (n = 6 for each condition).
